Gujarat Themis Biosyn shares surged over 15% as the company announced plans to acquire 13 anti-TB and anti-infective brands from Sanofi for Euro 158 million. The deal, expected to close by December 2026, will enhance earnings and expand its global pharmaceutical presence.